Clinical Trial Update: The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the prevalence of iron deficiency and the effectiveness of Ferinject in patients with heart failure with preserved ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Iron Deficiency

Drugs mentioned

• Ferinject (ferric carboxymaltose)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Chronic Heart Failure, Iron Deficiency, Latent | Phase 4 | Status: RECRUITING